PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34502335-0	2021	Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation.	Larazotide	45-55	haptoglobin	Homo sapiens	27-34	
33397225-0	2021	The therapeutic use of the zonulin inhibitor AT-1001 (Larazotide) for a variety of acute and chronic inflammatory diseases.	Larazotide	54-64	haptoglobin	Homo sapiens	27-34	
35211683-0	2022	Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series.	Larazotide	20-30	haptoglobin	Homo sapiens	0-7	
35211683-5	2022	Larazotide, a zonulin inhibitor, prevents breakdown of tight junctions, limiting antigen trafficking.	Larazotide	0-10	haptoglobin	Homo sapiens	14-21	
33397225-2	2021	In this scenario, Larazotide, a zonulin antagonist, could be employed as a viable therapeutic strategy.	Larazotide	18-28	haptoglobin	Homo sapiens	32-39	
33397225-3	2021	OBJECTIVE: The present review aims to describe recent research and current observations about zonulin involvement in several diseases and the use of its inhibitor Larazotide for their treatment.	Larazotide	163-173	haptoglobin	Homo sapiens	94-101	
33397225-7	2021	CONCLUSIONS: A substantial role of zonulin in many chronic and acute inflammatory diseases has been demonstrated in both in vivo and in vitro, indicating the possible efficacy of a Larazotide treatment.	Larazotide	181-191	haptoglobin	Homo sapiens	35-42